BiotechTube

Swine Influenza

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Prophylaxis of A/H3N2v Influenza

Conditions

Prophylaxis of A/H3N2v Influenza

Trial Timeline

May 1, 2013 → Sep 1, 2014

NCT ID
NCT01855945

About Swine Influenza

Swine Influenza is a phase 1 stage product being developed by Novartis for Prophylaxis of A/H3N2v Influenza. The current trial status is completed. This product is registered under clinical trial identifier NCT01855945. Target conditions include Prophylaxis of A/H3N2v Influenza.

What happened to similar drugs?

2 of 13 similar drugs in Prophylaxis of A/H3N2v Influenza were approved

Approved (2) Terminated (2) Active (10)
✅daptomycin 6 mg/kg IVMerckApproved
✅voriconazolePfizerApproved
🔄AtogepantAbbViePhase 3
🔄Esomeprazole + CimetidineAstraZenecaPhase 3
❌ISL + FTC/TDF + FTC/TAF + Placebo to ISL + Placebo to FTC/TDF + Placebo to FTC/TAFMerckPhase 3
🔄TIVc_LOT A + TIVc_LOT B + TIVc_LOT C + TIVfNovartisPhase 3
🔄rabies vaccineNovartisPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01855945Phase 1Completed

Competing Products

20 competing products in Prophylaxis of A/H3N2v Influenza

See all competitors
ProductCompanyStageHype Score
MicafunginAstellas PharmaPre-clinical
26
E2007EisaiPhase 2
35
AtogepantAbbViePhase 3
47
Esomeprazole + CimetidineAstraZenecaPhase 3
40
LetermovirMerckPhase 1
36
daptomycin 6 mg/kg IVMerckApproved
35
ISL + FTC/TDF + FTC/TAF + Placebo to ISL + Placebo to FTC/TDF + Placebo to FTC/TAFMerckPhase 3
32
TIVc_LOT A + TIVc_LOT B + TIVc_LOT C + TIVfNovartisPhase 3
40
rabies vaccineNovartisPhase 3
40
Fluad H5N1 Pandemic Influenza VaccineNovartisPhase 2
35
H5N1 Influenza Vaccine + H5N1 Influenza VaccineNovartisPhase 2
35
Oral Lenacapavir (LEN) + Subcutaneous (SC) Lenacapavir (LEN) + F/TAF + F/TDF + Placebo SC LEN + PTM Oral LEN + PTM F/TAF + PTM F/TDFGilead SciencesPhase 3
44
coformulated TDF/FTCGilead SciencesPre-clinical
26
Lenacapavir Tablet + Lenacapavir Injection + Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF)Gilead SciencesPhase 2
39
Oral Lenacapavir (LEN) + F/TDF + Sub-cutaneous (SC) Lenacapavir (LEN) + Placebo SC LEN + PTM F/TDF + PTM Oral LEN + F/TAF (for US participants only)Gilead SciencesPhase 3
44
Lenacapavir Injection + Lenacapavir TabletGilead SciencesPhase 3
47
Lenacapavir Injection + Lenacapavir Tablet + Emtricitabine/tenofovir disoproxil fumarate (F/TDF)Gilead SciencesPhase 2
39
F/TAF + F/TDF + F/TAF Placebo + F/TDF PlaceboGilead SciencesPhase 3
44
Lenacapavir Injection + Lenacapavir Tablet + Emtricitabine/tenofovir disoproxil fumarate (F/TDF)Gilead SciencesPhase 2
39
azithromycin (AZ) microsphere + test chloroquine (CQ) formulation + azithromycin (AZ) + chloroquine (CQ)PfizerPhase 1
29